Lord Warner

To ask His Majesty's Government what consideration they have given to extending the measures in the youth justice system concerning reduced custody lengths to male offenders aged between 18 and 21.

To ask His Majesty's Government when was the last year that the NHS in England achieved (1) its four-hour target for A&E waiting times, (2) its 62-day target for cancer treatment, and (3) an average waiting time for elective surgery under six months.

To ask His Majesty's Government what proportion of NHS acute hospital trusts currently have average waiting times for elective surgery over six months; and what are the names of those trusts.

To ask His Majesty's Government what proportion of acute hospital trusts in England regularly conduct NHS operations on (1) Saturdays, and (2) Sundays; and whether this information is able to be published so that patients may exercise choice.

To ask His Majesty's Government what progress they have made with the establishment of pilot schemes to assess the feasibility of introducing a common identifier for children across health, care, and education services.

To ask His Majesty's Government what plans they have to refer the Impact Assessment for the 2023 Statutory Scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.

To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what policy options were included in the Department of Health and Social Care's long list as alternative...

To ask His Majesty's Government what plans they have to introduce an end of scheme reconciliation exercise for the Statutory Scheme to control the cost of branded health services medicines.

To ask His Majesty's Government, further to the Proposed update to the 2023 Statutory Scheme to control the cost of branded medicines, whether the 2 per cent cap in growth in the cost of branded medicines was assessed against (1) inflation expectations, a...

To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what analysis and evidence the Department of Health and Social Care considered when it proposed to keep ...

To ask His Majesty's Government what is the evidence that the Department of Health and Social Care used to support the statement in the consultation on the Statutory Scheme to control the cost of branded health services medicines that investment in resear...

To ask His Majesty's Government, further to the Written Answers by Lord Markham on 27 June (HL8632, HL8633), how many Voluntary Scheme for Branded Medicines Pricing and Access-related price increase applications were submitted in each year from 2019 to 20...

To ask His Majesty's Government, further to the Written Answers by Lord Markham on 27 June (HL8632, HL8633), what assessment they have made of the impact of a reduced rebate for products that are rendered uneconomical by the Voluntary Scheme for Branded M...

To ask His Majesty's Government, further to the Written Answers by Lord Markham on 27 June (HL8632, HL8633), what is their response to the claim by the Association of the British Pharmaceutical Industry that international investors are "abandoning UK life...

To ask His Majesty's Government, further to the Written Answers by Lord Markham on 27 June (HL8632, HL8633), what was the estimated value of foreign direct investment in UK life sciences for each of the past three years for which such estimates are availa...

To ask His Majesty's Government what action they will take if any new organisation prescribes puberty blockers to children, other than as part of a clinical trial in accordance with the policy of NHS England.

To ask His Majesty's Government what regulatory arrangements are in place to ensure the safety of children and teenagers in respect of any private organisation providing puberty blocking hormonal treatment or gender surgery.

To ask His Majesty's Government what assessment they have made of whether the Voluntary Scheme for Branded Medicines Pricing and Access has caused a reduction in the supply of biosimilar medicines, and any associated impact on (1) patient outcomes, (2) NH...

To ask His Majesty's Government what volume of sales under the Voluntary Scheme for Branded Medicines Pricing and Access are off-patent medicines; and how the suppliers of such medicines are represented in negotiations for the next scheme.

To ask His Majesty's Government whether the proposed report on a consistent child identifier (CCI) as provided under section 179 of the Health and Social Care Act 2022 will ensure that a CCI relates to both (1) children’s health and social care, and (2) t...